Keywords: efpia, proposals, restore, european, pharma, competitiveness, during
EFPIA proposals to restore European pharma's competitiveness
Article | 22 June 2001
During 1990-2000, average annual growth for pharmaceutical sales inEurope remained below 10%, while in the USA the average was 15%. During the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
